Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 1, 2012

Primary Completion Date

February 9, 2017

Study Completion Date

July 17, 2020

Conditions
Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedStage IB2 Cervical Cancer AJCC v6 and v7Stage II Cervical Cancer AJCC v7Stage IIA Cervical Cancer AJCC v7Stage IIB Cervical Cancer AJCC v6 and v7Stage IIIB Cervical Cancer AJCC v6 and v7Stage IVA Cervical Cancer AJCC v6 and v7
Interventions
DRUG

Cisplatin

Given IV

RADIATION

External Beam Radiation Therapy

Undergo external beam radiation therapy

RADIATION

Internal Radiation Therapy

Undergo intracavitary brachytherapy

BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (16)

10461

Montefiore Medical Center-Einstein Campus, The Bronx

19107

Thomas Jefferson University Hospital, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

23298

Virginia Commonwealth University/Massey Cancer Center, Richmond

30912

Augusta University Medical Center, Augusta

44106

Case Western Reserve University, Cleveland

44195

Cleveland Clinic Foundation, Cleveland

73104

University of Oklahoma Health Sciences Center, Oklahoma City

87102

University of New Mexico Cancer Center, Albuquerque

90033

Los Angeles County-USC Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

92868

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

95817

University of California Davis Comprehensive Cancer Center, Sacramento

06102

Hartford Hospital, Hartford

06050

The Hospital of Central Connecticut, New Britain

02905

Women and Infants Hospital, Providence

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

NRG Oncology

OTHER

lead

National Cancer Institute (NCI)

NIH